FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC By Ogkologos - July 29, 2026 7 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive, Somatostatin Receptor-Positive GEP NETs Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC EMA Recommends Extension of Therapeutic Indications for Epcoritamab MOST POPULAR Durvalumab Extends Lives of People with Early-Stage Small Cell Lung Cancer June 25, 2024 Prognostic Role of ctDNA in Patients with Surgically Resectable Colorectal Cancer January 30, 2023 Sofi Leota Was Diagnosed With Breast Cancer At 23. Two Years... July 23, 2020 This Company Is Turning Scrap Wood Into 10,000+ Guitars For Sick... October 4, 2019 Load more HOT NEWS Health inequalities: Why is it harder for some people to eat... EMA Recommends Granting a Conditional Marketing Authorisation for Ciltacabtagene Autoleucel 10 Ways to Keep Your Family Safe from the Coronavirus Outbreak ESMO Manifesto – Translating Scientific Evidence Into Effective Public Health Policy
